Medical Genomics Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon 305-806, Republic of Korea.
Clin Chim Acta. 2013 Jan 16;415:12-9. doi: 10.1016/j.cca.2012.09.003. Epub 2012 Sep 10.
Carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6) inhibits anoikis and affects the malignant phenotype of cancer cells. In this study, we analyzed CEACAM6 as a gene that is highly upregulated in colon cancer tissues, and examined the assertion that CEACAM6 might be a suitable candidate tumor marker for the diagnosis of colon cancer.
CEACAM6 gene expression in human colon tissues was performed by tissue microarray and analyzed using RT-PCR (each of normal and tumor tissue, n=40) and immunohistochemical and clinicopathological (colon cancer patients, n=143) analyses.
CEACAM6 transcriptional and translational levels were significantly upregulated in human tumor tissues compared to non-tumor regions, and clinicopathological analysis revealed a significant correlation between CEACAM6 protein expression and Dukes' stage (p<0.001). High expression levels of CEACAM6 were significantly associated with lower overall survival (p<0.001) and shorter recurrence-free survival (p<0.001). We demonstrated that knockdown of CEACAM6 with CEACAM6-specific small interfering RNA in colorectal cancer cells attenuated invasivity (35%); conversely, the overexpression of CEACAM6 increased invasiveness.
CEACAM6 is significantly upregulated in colon cancer tissues and is closely associated with poor prognosis, indicating that CEACAM6 might be used as a tumor biomarker and a potential therapeutic target for colon cancer.
癌胚抗原相关细胞黏附分子 6（CEACAM6）抑制失巢凋亡，影响癌细胞的恶性表型。本研究分析了 CEACAM6 在结肠癌组织中高表达的基因，并验证了 CEACAM6 可能是结肠癌诊断的合适候选肿瘤标志物的观点。
采用组织微阵列分析人结肠癌组织中 CEACAM6 基因的表达，并用 RT-PCR（每组正常和肿瘤组织，n=40）和免疫组织化学及临床病理（结肠癌患者，n=143）分析进行分析。
CEACAM6 的转录和翻译水平在人肿瘤组织中明显高于非肿瘤区域，临床病理分析显示 CEACAM6 蛋白表达与 Dukes 分期之间存在显著相关性（p<0.001）。CEACAM6 高表达水平与总生存期（p<0.001）和无复发生存期（p<0.001）显著缩短相关。我们证明，用针对 CEACAM6 的特异性小干扰 RNA 敲低结直肠癌细胞中的 CEACAM6 可减弱侵袭性（35%）；相反，CEACAM6 的过表达则增加了侵袭性。
CEACAM6 在结肠癌组织中显著上调，并与不良预后密切相关，表明 CEACAM6 可能用作结肠癌的肿瘤标志物和潜在的治疗靶点。
